drugset / Trial / NCT03802162

A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355

NCT03802162

Phase 1 Completed 60 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-355.

Timeline

Start
2019-02-15
Primary completion
2019-05-10
Completion
2019-08-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Donepezil Small molecule
Subject Memantine Unknown 10 mg
Subject Memantine Unknown 20 mg

Indications